(−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection

Group-III metabotropic glutamate receptors (mGluR4, -6, -7, and -8) modulate neurotoxicity of excitatory amino acids and beta-amyloid-peptide (betaAP), as well as epileptic convulsions, most likely via presynaptic inhibition of glutamatergic neurotransmission. Due to the lack of subtype-selective ligands for group-III receptors, we previously utilized knock-out mice to identify mGluR4 as the primary receptor mediating neuroprotection of unselective group-III agonists such as L-AP(4) or (+)-PPG, whereas mGluR7 is critical for anticonvulsive effects. In a recent effort to find group-III subtype-selective drugs we identified (+/-)-PHCCC as a positive allosteric modulator for mGluR4. This compound increases agonist potency and markedly enhances maximum efficacy and, at higher concentrations, directly activates mGluR4 with low efficacy. All the activity of (+/-)-PHCCC resides in the (-)-enantiomer, which is inactive at mGluR2, -3, -5a, -6, -7b and -8a, but shows partial antagonist activity at mGluR1b (30% maximum antagonist efficacy). Chimeric receptor studies showed that the binding site of (-)-PHCCC is localized in the transmembrane region.Finally, (-)-PHCCC showed neuroprotection against betaAP- and NMDA-toxicity in mixed cultures of mouse cortical neurons. This neuroprotection was additive to that induced by the highly efficacious mGluR1 antagonist CPCCOEt and was blocked by MSOP, a group-III mGluR antagonist. Our data provide evidence for a novel pharmacological site on mGluR4, which may be used as a target-site for therapeutics.

[1]  F. Gasparini,et al.  The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors* , 2000, The Journal of Biological Chemistry.

[2]  M. Behrens,et al.  Antagonists for group I mGluRs attenuate excitotoxic neuronal death in cortical cultures , 1998, The European journal of neuroscience.

[3]  D. Choi,et al.  4 – Cytotoxicity in Murine Neocortical Cell Culture , 1993 .

[4]  J. Kemp,et al.  Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K. Reymann,et al.  Neuroprotection against hypoxic/hypoglycaemic injury after the insult by the group III metabotropic glutamate receptor agonist (R,S)‐4‐phosphonophenylglycine , 2000, British Journal of Pharmacology.

[6]  K. Maiese,et al.  Group I and Group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection , 2000, Journal of neuroscience research.

[7]  P Hiselius,et al.  The New Generation , 2021, The Women's Liberation Movement in Russia.

[8]  F. Nicoletti,et al.  Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors , 1999, Neuropharmacology.

[9]  C. Elger,et al.  Up‐regulation of the metabotropic glutamate receptor mGluR4 in hippocampal neurons with reduced seizure vulnerability , 2000, Annals of neurology.

[10]  Roland Heckendorn,et al.  2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist , 1999, Neuropharmacology.

[11]  F. Gasparini,et al.  Selective Activation of mGlu4 Metabotropic Glutamate Receptors Is Protective against Excitotoxic Neuronal Death , 2000, The Journal of Neuroscience.

[12]  T. Knöpfel,et al.  Profiling of trans-azetidine-2,4-dicarboxylic acid at the human metabotropic glutamate receptors mGlu1b, -2, -4a and -5a. , 1995, European journal of pharmacology.

[13]  H. Tse,et al.  α-methyl derivatives of serine-O-phosphate as novel, selective competitive metabotropic glutamate receptor antagonists , 1996, Neuropharmacology.

[14]  F. Nicoletti,et al.  Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  J. Cano,et al.  Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+‐induced neurotoxicity along with brain‐derived neurotrophic factor induction , 2001, Journal of neurochemistry.

[16]  S. D’Mello,et al.  Insulin-Like Growth Factor and Potassium Depolarization Maintain Neuronal Survival by Distinct Pathways: Possible Involvement of PI 3-Kinase in IGF-1 Signaling , 1997, The Journal of Neuroscience.

[17]  T. Knöpfel,et al.  A Novel Splice Variant of a Metabotropic Glutamate Receptor, Human mGluR7b , 1997, Neuropharmacology.

[18]  F. Nicoletti,et al.  The Neuroprotective Activity of Group-II Metabotropic Glutamate Receptors Requires New Protein Synthesis and Involves a Glial–Neuronal Signaling , 1997, The Journal of Neuroscience.

[19]  K. Bales,et al.  Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795 , 1999 .

[20]  Scott Nawy,et al.  Suppression by glutamate of cGMP-activated conductance in retinal bipolar cells , 1990, Nature.

[21]  F. Gasparini,et al.  Neuroprotective activity of metabotropic glutamate receptor ligands. , 2002, Advances in experimental medicine and biology.

[22]  F. Gasparini,et al.  SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. , 1999, The Journal of pharmacology and experimental therapeutics.

[23]  F. Nicoletti,et al.  Molecular determinants of metabotropic glutamate receptor signaling. , 2001, Trends in pharmacological sciences.

[24]  J. M. Mathiesen,et al.  Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB‐1893 and MPEP , 2003, British journal of pharmacology.

[25]  E. Meli,et al.  1‐Aminoindan‐1,5‐dicarboxylic acid and (S)‐(+)‐2‐(3′‐carboxybicyclo[1.1.1] pentyl)‐glycine, two mGlu1 receptor‐preferring antagonists, reduce neuronal death in in vitro and in vivo models of cerebral ischaemia , 1999, The European journal of neuroscience.

[26]  K. Mangano,et al.  Activation of Group III Metabotropic Glutamate Receptors Inhibits the Production of RANTES in Glial Cell Cultures , 2002, The Journal of Neuroscience.

[27]  Ayae Kinoshita,et al.  Differential Presynaptic Localization of Metabotropic Glutamate Receptor Subtypes in the Rat Hippocampus , 1997, The Journal of Neuroscience.

[28]  J. Pin,et al.  New perspectives for the development of selective metabotropic glutamate receptor ligands. , 1999, European journal of pharmacology.

[29]  F. Nicoletti,et al.  Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. , 1996, European journal of pharmacology.

[30]  S W Scherer,et al.  Localization of the human mGluR4 gene within an epilepsy susceptibility locus(1). , 2001, Brain research. Molecular brain research.

[31]  R. Shigemoto,et al.  mGluR7‐like metabotropic glutamate receptors inhibit NMDA‐mediated excitotoxicity in cultured mouse cerebellar granule neurons , 1999, The European journal of neuroscience.

[32]  S. Urwyler,et al.  Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. , 2001, Molecular pharmacology.

[33]  P. Calabresi,et al.  Selective Blockade of Type-1 Metabotropic Glutamate Receptors Induces Neuroprotection by Enhancing Gabaergic Transmission , 2001, Molecular and Cellular Neuroscience.

[34]  F. Nicoletti,et al.  Retracted: Neuroprotection mediated by glial group‐II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol‐3‐kinase pathways , 2001, Journal of neurochemistry.

[35]  A. Caricasole,et al.  Native group‐III metabotropic glutamate receptors are coupled to the mitogen‐activated protein kinase/phosphatidylinositol‐3‐kinase pathways , 2002, Journal of neurochemistry.

[36]  C. Hsiao,et al.  A [35S]GTPγS binding assessment of metabotropic glutamate receptor standards in Chinese hamster ovary cell lines expressing the human metabotropic receptor subtypes 2 and 4 , 1998, Neuropharmacology.

[37]  E. Meli,et al.  Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time-course and mechanisms , 1999, Neuropharmacology.

[38]  F. Gasparini,et al.  CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. , 1999, Molecular pharmacology.

[39]  D. Hall,et al.  Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. , 2000, Molecular pharmacology.

[40]  T. Knöpfel,et al.  The agonist selectivity of a class III metabotropic glutamate receptor, human mGluR4a, is determined by the N-terminal extracellular domain , 1995, Neuroreport.

[41]  P. Suzdak,et al.  L-2-amino-4-phosphonobutyrate (L-AP4) is an agonist at the type IV metabotropic glutamate receptor which is negatively coupled to adenylate cyclase. , 1993, European journal of pharmacology.

[42]  J. Cano,et al.  DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury , 2002, Neuroscience.

[43]  K. Maiese,et al.  Activation of the metabotropic glutamate receptor is neuroprotective during nitric oxide toxicity in primary hippocampal neurons of rats , 1995, Neuroscience Letters.

[44]  Burton S. Rosner,et al.  Neuropharmacology , 1958, Nature.

[45]  D. Laurie,et al.  (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.

[46]  T. Knöpfel,et al.  The C‐Terminal Domain of the mGluR1 Metabotropic Glutamate Receptor Affects Sensitivity to Agonists , 1996, Journal of neurochemistry.

[47]  J. Penney,et al.  The Role of Group I and Group II Metabotropic Glutamate Receptors in Modulation of Striatal NMDA and Quinolinic Acid Toxicity , 2001, Experimental Neurology.

[48]  F. Nicoletti,et al.  Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. , 1995, Molecular pharmacology.

[49]  L. Prézeau,et al.  A model for the functioning of family 3 GPCRs. , 2002, Trends in pharmacological sciences.

[50]  T. Knöpfel,et al.  Molecular Cloning, Functional Expression and Pharmacological Characterization of the Human Metabotropic Glutamate Receptor Type 2 , 1995, The European journal of neuroscience.

[51]  G. Siggins,et al.  Metabotropic glutamate receptors regulate N-methyl-D-aspartate-mediated synaptic transmission in nucleus accumbens. , 1997, Journal of neurophysiology.

[52]  R. Tsien,et al.  A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.

[53]  T. Knöpfel,et al.  Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 4 , 1995, Neuropharmacology.

[54]  F. Nicoletti,et al.  Neuroprotection by Glial Metabotropic Glutamate Receptors Is Mediated by Transforming Growth Factor-β , 1998, The Journal of Neuroscience.

[55]  U. Dirnagl,et al.  Distinct influence of the group III metabotropic glutamate receptor agonist (R,S)-4-phosphonophenylglycine [(R,S)-PPG] on different forms of neuronal damage , 2000, Neuropharmacology.

[56]  S. Lazareno,et al.  Pharmacological characterization of acetylcholine‐stimulated [35S]‐GTPγS binding mediated by human muscarinic m1–m4 receptors: antagonist studies , 1993, British journal of pharmacology.